Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.

Abstract	Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.
Authors	Patrick L Alore, Walter M Jay, Mícheál P Macken
Journal	Seminars in ophthalmology (Semin Ophthalmol) 2006 Jan-Mar Vol. 21 Issue 1 Pg. 15-7 ISSN: 0882-0538 [Print] England
PMID	16517439 (Publication Type: Journal Article, Review)
Chemical References	Neuroprotective Agents Topiramate Fructose
Topics	Drug Prescriptions Fructose (adverse effects, analogs & derivatives, therapeutic use) Glaucoma (chemically induced) Humans Neuroprotective Agents (adverse effects, therapeutic use) Pseudotumor Cerebri (drug therapy) Risk Factors Topiramate Treatment Outcome Weight Loss (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!